Lilly’s GLP-1 windfall fuels M&A ‘land grab’ across 10 deals, $25B
· amanda lanier
AI Briefing
- • Eli Lilly's revenue surged $19.8B in Q1 2026, driven by GLP-1 drugs tirzepatide and zepbound.
- • Lilly is fueling an M&A 'land grab' with $25.1B in announced deals this year.
- • The company has closed over $26B in deals, with more expected.
Context
Eli Lilly and Co. has reported $19.8 billion in revenue for the first quarter of 2026, largely due to the success of its GLP-1 drugs tirzepatide, marketed as Mounjaro and Zepbound. The company's revenue is driven by the sales of these drugs for type 2 diabetes and obesity.
The revenue generated from these blockbuster drugs is being used to fund an aggressive dealmaking campaign, with the company announcing acquisitions totaling $25.1 billion across 10 deals so far this year, in addition to over $26 billion in other closed deals.
Advertisement